Immunohistochemical expression of bcl-2, bcl-x, and bax in follicular carcinomas of the thyroid

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 4, 2006, Pages 417-421

  Haynik, Denise M ^a   Prayson, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bax; Bcl 2; Bcl x; Follicular carcinoma; Thyroid

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; THYROID GLAND; THYROID NEOPLASMS;

EID: 33751359448     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000205061.50044.13     Document Type: Article

References (28)

1. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
2. Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med. 1997;48:267-281.
3. Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440-1443.
4. Seto M, Jaeger U, Hockett RD, et al. Alternative promoters and exons, somatic mutation, and deregulation of bcl-2/Ig fusion gene in lymphoma. EMBO J. 1988;7:123-131.
5. Reed J, Tsujimoto Y, Epstein S, et al. Regulation of bcl-2 gene expression in lymphoid cell lines containing t(14;18) or normal #18 chromosomes. Oncogene Res. 1989;7:93.
6. Reed JC. bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994;124:1-6.
7. Boise LH, Gonzalez-Garcia M, Postema CE, et al. bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74:597-608.
8. Oltvai ZN, Milliman CL, Korsmeyer SJ. bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
9. Sato T, Hanada M, Bodrug S, et al. Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci U S A. 1994;91:9238-9242.
10. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-supressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993;143:390-400.
11. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small cell lung carcinoma. N Engl J Med. 1993;329:690-694.
12. Joensuu H, Pylkkanen L, Toikkanen S. bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol. 1994;145:1101-1198.
13. Hague A, Moorghen M, Hicks D, et al. bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene. 1994;9:3367-3370.
14. Haynik D, Prayson R. Immunohistochemical expression of COX-2 in follicular carcinoma of the thyroid. Arch Pathol Lab Med. 2005;129:736-741.
15. Branet F, Brousset P, Krajewski S, et al. Expression of cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. J Clin Endocrinol Metab. 1996;81:2726-2730.
16. Pilotti S, Collini P, Rilke F, et al. bcl-2 expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol. 1994;172:337-342.
17. Baretton GB, Diebold J, Felchner M, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas: aspects of carcinogenesis and prognostic significance. Cancer. 1996; 77:255-264.
18. Hellemans P, van Dam PA, Weyler J, et al. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 1995;72:354-360.
19. Lipponen P, Pietilainen T, Kosma V-M, et al. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favorable prognosis. J Pathol. 1995;177:49-55.
20. Pietenpol JA, Papadopoulos N, Markowitz S, et al. Paradoxical inhibition of solid tumors cell growth by bcl-2. Cancer Res. 1994;54:3714-3717.
21. Theodorakis P, D'Sa-Eipper C, Subramanian T, et al. Unmasking of a proliferation-restraining activity of the anti-apoptosis protein EBV BHRF1. Oncogene. 1996;12:1707-1713.
22. Cheng EHY, Kirsch DG, Clem RJ, et al. Conversion of bcl-2 to a BAX-like death effector by caspases. Science. 1997;278:1966-1968.
23. Hermann S, Sturm I, Mrozek A, et al. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type p53 is associated with a high bax and p21 expression in thyroid carcinoma. Int J Cancer. 2001;92:805-811.
24. Strum I, Kohne CH, Wolff G, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastasis. J Clin Oncol. 1999;17:1364-74.
25. Wagener C, Bargou RC, Danielk PT, et al. Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer. 1996;67:138-141.
26. Tai YT, Lee S, Niloff E, et al. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol. 1998;16:2583-2590.
27. Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995;55:4471-4478.
28. Jürgensmeier JM, Xie Z, Devereraux Q, et al. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci. 1998;95;49997-50002.